• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微生物组在卵巢癌治疗反应中的诊断和预后潜力。

Diagnostic and prognostic potential of the microbiome in ovarian cancer treatment response.

机构信息

Department of Surgery, Mayo Clinic, Rochester, MN, USA.

Microbiome Program, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.

出版信息

Sci Rep. 2023 Jan 13;13(1):730. doi: 10.1038/s41598-023-27555-x.

DOI:10.1038/s41598-023-27555-x
PMID:36639731
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9839674/
Abstract

Ovarian cancer (OC) is the second most common gynecological malignancy and the fifth leading cause of death due to cancer in women in the United States mainly due to the late-stage diagnosis of this cancer. It is, therefore, critical to identify potential indicators to aid in early detection and diagnosis of this disease. We investigated the microbiome associated with OC and its potential role in detection, progression as well as prognosis of the disease. We identified a distinct OC microbiome with general enrichment of several microbial taxa, including Dialister, Corynebacterium, Prevotella, and Peptoniphilus in the OC cohort in all body sites excluding stool and omentum which were not sampled from the benign cohort. These taxa were, however, depleted in the advanced-stage and high-grade OC patients compared to early-stage and low-grade OC patients suggestive of decrease accumulation in advanced disease and could serve as potential indicators for early detection of OC. Similarly, we also observed the accumulation of these mainly pathogenic taxa in OC patients with adverse treatment outcomes compared to those without events and could also serve as potential indicators for predicting patients' responses to treatment. These findings provide important insights into the potential use of the microbiome as indicators in (1) early detection of and screening for OC and (2) predicting patients' response to treatment. Given the limited number of patients enrolled in the study, these results would need to be further investigated and confirmed in a larger study.

摘要

卵巢癌(OC)是美国第二常见的妇科恶性肿瘤,也是女性癌症死亡的第五大主要原因,主要是因为这种癌症的晚期诊断。因此,确定潜在的指标以辅助早期发现和诊断这种疾病至关重要。我们研究了与 OC 相关的微生物组及其在检测、进展和疾病预后中的潜在作用。我们在所有除粪便和大网膜以外的身体部位的 OC 队列中确定了一个独特的 OC 微生物组,该微生物组普遍存在几种微生物类群,包括 Dialister、Corynebacterium、Prevotella 和 Peptoniphilus,而良性队列中没有这些微生物类群。然而,与早期和低级别 OC 患者相比,这些类群在晚期和高级别 OC 患者中减少,提示在晚期疾病中积累减少,可作为 OC 早期检测的潜在指标。同样,我们还观察到这些主要致病性类群在治疗结果不良的 OC 患者中积累,而在没有事件的患者中则没有,这也可以作为预测患者对治疗反应的潜在指标。这些发现为微生物组作为(1)OC 的早期检测和筛查以及(2)预测患者对治疗的反应的指标的潜在用途提供了重要的见解。鉴于研究中纳入的患者数量有限,这些结果需要在更大的研究中进一步研究和证实。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31b3/9839674/5a39028c1b29/41598_2023_27555_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31b3/9839674/97e5da5227a5/41598_2023_27555_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31b3/9839674/4b8ba87477b6/41598_2023_27555_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31b3/9839674/8c0ff9ea5e1c/41598_2023_27555_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31b3/9839674/9dcd1287dd99/41598_2023_27555_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31b3/9839674/62e90113499c/41598_2023_27555_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31b3/9839674/8bae8a3bee7d/41598_2023_27555_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31b3/9839674/5a39028c1b29/41598_2023_27555_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31b3/9839674/97e5da5227a5/41598_2023_27555_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31b3/9839674/4b8ba87477b6/41598_2023_27555_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31b3/9839674/8c0ff9ea5e1c/41598_2023_27555_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31b3/9839674/9dcd1287dd99/41598_2023_27555_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31b3/9839674/62e90113499c/41598_2023_27555_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31b3/9839674/8bae8a3bee7d/41598_2023_27555_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31b3/9839674/5a39028c1b29/41598_2023_27555_Fig7_HTML.jpg

相似文献

1
Diagnostic and prognostic potential of the microbiome in ovarian cancer treatment response.微生物组在卵巢癌治疗反应中的诊断和预后潜力。
Sci Rep. 2023 Jan 13;13(1):730. doi: 10.1038/s41598-023-27555-x.
2
Urinary interleukin-1β levels among gynecological patients.妇科患者的尿白细胞介素-1β水平
J Ovarian Res. 2014 Nov 18;7:104. doi: 10.1186/s13048-014-0104-4.
3
Approaches to the detection of ovarian cancer.卵巢癌的检测方法。
Scand J Clin Lab Invest Suppl. 2016;245:S49-53. doi: 10.1080/00365513.2016.1208452. Epub 2016 Jul 19.
4
Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.卵巢癌新出现的诊断、预后和治疗生物标志物。
Cell Oncol (Dordr). 2017 Apr;40(2):105-118. doi: 10.1007/s13402-016-0309-1. Epub 2016 Dec 15.
5
Next-generation sequencing-based genomic profiling analysis reveals novel mutations for clinical diagnosis in Chinese primary epithelial ovarian cancer patients.基于新一代测序的基因组分析揭示了中国原发性上皮性卵巢癌患者临床诊断的新突变。
J Ovarian Res. 2019 Feb 20;12(1):19. doi: 10.1186/s13048-019-0494-4.
6
Screening program in ovarian cancer: A logical step in clinical management? A meta-analysis.卵巢癌筛查项目:临床管理中的合理举措?一项荟萃分析。
Curr Probl Cancer. 2018 Mar-Apr;42(2):235-240. doi: 10.1016/j.currproblcancer.2017.12.005. Epub 2018 Jan 5.
7
Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer.评估腹膜微生物特征和肿瘤标志物水平作为卵巢癌的潜在诊断工具。
PLoS One. 2020 Jan 9;15(1):e0227707. doi: 10.1371/journal.pone.0227707. eCollection 2020.
8
Metabolomic biomarkers for benign conditions and malignant ovarian cancer: Advancing early diagnosis.代谢组学生物标志物在良性疾病和卵巢癌恶性肿瘤中的应用:推进早期诊断。
Clin Chim Acta. 2024 Jun 15;560:119734. doi: 10.1016/j.cca.2024.119734. Epub 2024 May 21.
9
Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.卵巢癌中枢纽基因和治疗药物的筛选的综合生物信息学分析。
J Ovarian Res. 2020 Jan 27;13(1):10. doi: 10.1186/s13048-020-0613-2.
10
Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer.微小RNA在卵巢癌预后、诊断及治疗中的差异作用
Biomed Pharmacother. 2016 Dec;84:592-600. doi: 10.1016/j.biopha.2016.09.087. Epub 2016 Sep 30.

引用本文的文献

1
A Natural Language Processing Method Identifies an Association Between Bacterial Communities in the Upper Genital Tract and Ovarian Cancer.一种自然语言处理方法确定了上生殖道细菌群落与卵巢癌之间的关联。
Int J Mol Sci. 2025 Aug 1;26(15):7432. doi: 10.3390/ijms26157432.
2
Gut-Vaginal Microbiome Crosstalk in Ovarian Cancer: Implications for Early Diagnosis.卵巢癌中的肠道-阴道微生物群串扰:对早期诊断的意义
Pathogens. 2025 Jun 25;14(7):635. doi: 10.3390/pathogens14070635.
3
The role of diet, obesity and body composition in epithelial ovarian cancer development and progression: Mechanisms and therapeutic implications.

本文引用的文献

1
LinDA: linear models for differential abundance analysis of microbiome compositional data.LinDA:用于微生物组组成数据差异丰度分析的线性模型
Genome Biol. 2022 Apr 14;23(1):95. doi: 10.1186/s13059-022-02655-5.
2
Invasion of Endometrial Cancer Cells.子宫内膜癌细胞的侵袭
Front Microbiol. 2021 Jul 23;12:674835. doi: 10.3389/fmicb.2021.674835. eCollection 2021.
3
Shifts in gut and vaginal microbiomes are associated with cancer recurrence time in women with ovarian cancer.肠道和阴道微生物群的变化与卵巢癌女性患者的癌症复发时间相关。
饮食、肥胖和身体成分在上皮性卵巢癌发生发展中的作用:机制及治疗意义
Gynecol Oncol Rep. 2025 Mar 16;58:101718. doi: 10.1016/j.gore.2025.101718. eCollection 2025 Apr.
4
Therapeutic potential of microbiome modulation in reproductive cancers.微生物群调节在生殖系统癌症中的治疗潜力
Med Oncol. 2025 Apr 6;42(5):152. doi: 10.1007/s12032-025-02708-2.
5
Translational Implications of The Gut Microbiome in Women with A Benign or Malignant Pelvic Mass.肠道微生物群在患有良性或恶性盆腔肿块女性中的转化意义
Ann Obstet Gynecol. 2025;8(1). Epub 2025 Feb 12.
6
The Urogenital System Microbiota: Is It a New Gamechanger in Urogenital Cancers?泌尿生殖系统微生物群:它会成为泌尿生殖系统癌症治疗的新变革因素吗?
Microorganisms. 2025 Feb 1;13(2):315. doi: 10.3390/microorganisms13020315.
7
Characterization of vaginal microbiomes in clinician-collected bacterial vaginosis diagnosed samples.临床医生收集的细菌性阴道病诊断样本中阴道微生物群的特征分析。
Microbiol Spectr. 2025 Apr;13(4):e0258224. doi: 10.1128/spectrum.02582-24. Epub 2025 Feb 25.
8
PTTM: dissecting the profile of tumor tissue microbiome to reveal microbiota features and associations with host transcriptome.肺肿瘤血栓性微血管病:剖析肿瘤组织微生物组特征以揭示微生物群特征及其与宿主转录组的关联
Brief Bioinform. 2024 Nov 22;26(1). doi: 10.1093/bib/bbaf057.
9
Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer.肠道微生物群与卵巢癌患者的PARP抑制剂疗效相关。
J Gynecol Oncol. 2025 May;36(3):e38. doi: 10.3802/jgo.2025.36.e38. Epub 2024 Oct 21.
10
The Gut Microbiome in Aging and Ovarian Cancer.衰老与卵巢癌中的肠道微生物群
Aging Cancer. 2024 Jun;5(1-2):14-34. doi: 10.1002/aac2.12071. Epub 2024 Jun 20.
PeerJ. 2021 Jun 17;9:e11574. doi: 10.7717/peerj.11574. eCollection 2021.
4
The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling.微生物组在卵巢癌中的作用:共生肿瘤发生和细菌代谢产物信号转导的机制见解。
Mol Med. 2021 Apr 1;27(1):33. doi: 10.1186/s10020-021-00295-2.
5
-a new functional genus with potential probiotic properties?是否存在具有潜在益生菌特性的新功能属?
Gut Microbes. 2021 Jan-Dec;13(1):1-21. doi: 10.1080/19490976.2021.1875796.
6
Relationship between ascites volume and clinical outcomes in epithelial ovarian cancer.上皮性卵巢癌腹水量与临床结局的关系
J Obstet Gynaecol Res. 2021 Apr;47(4):1527-1535. doi: 10.1111/jog.14682. Epub 2021 Jan 27.
7
Changes to the cervicovaginal microbiota and cervical cytokine profile following surgery for cervical intraepithelial neoplasia.宫颈上皮内瘤变手术后宫颈阴道微生物群和宫颈细胞因子谱的变化。
Sci Rep. 2021 Jan 25;11(1):2156. doi: 10.1038/s41598-020-80176-6.
8
Eubacterium rectale contributes to colorectal cancer initiation via promoting colitis.直肠真杆菌通过促进结肠炎导致结直肠癌的发生。
Gut Pathog. 2021 Jan 12;13(1):2. doi: 10.1186/s13099-020-00396-z.
9
Facklamia hominis bacteremia after transurethral resection of the prostate: a case report.人福克勒姆菌菌血症经尿道前列腺切除术:病例报告。
BMC Urol. 2020 Dec 7;20(1):192. doi: 10.1186/s12894-020-00762-8.
10
Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD.非肥胖型非酒精性脂肪性肝病患者中与显著肝纤维化相关的肠道微生物组和代谢物的独特特征。
Nat Commun. 2020 Oct 5;11(1):4982. doi: 10.1038/s41467-020-18754-5.